News

Johnson & Johnson Announces Price Reduction for Bedaquiline

Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the price of USD340 per six-month treatment course for more than 135 eligible countries. This initiative was done with support from the Global Fund to Fight AIDS, Tuberculosis, and Malaria and USAID. 

The move has been praised by Médecins Sans Frontières as an important step forward in the fight against TB. 

“In a world filled with worrying news, this new agreement is a welcome development and one that will help us move closer to the United Nations High-Level Meeting target of treating 1.5 million people with DR-TB by 2022,” said Dr. Lucica Ditiu, M.D., Executive Director of the Stop TB Partnership.

To read more about Johnson & Johnson and the Stop TB Partnership's announcement on bedaquiline's price reduction, please visit the Stop TB Partnership website here

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...